UK Companies House feature
CRESSET BIOMOLECULAR DISCOVERY LIMITED
Cash
£2M
+44.9% vs 2021
Net assets
£2M
+51.2% vs 2021
Employees
46
+48.4% vs 2021
Profit before tax
—
Period ending 2022-03-31
Profile
- Company number
- 04151475
- Status
- Active
- Incorporation
- 2001-01-31
- Last accounts made up
- 2025-03-31
- Account category
- GROUP
- Primary SIC
- 62012
Net assets
2-year trend · vs UK AI & Enterprise SaaS median
Accounts
2-year trend · latest 2022-03-31
| Metric | Trend | 2021-03-31 | 2022-03-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | — | — | |
| Net profit | — | — | |
| Cash | £1,393,693 | £2,019,479 | |
| Total assets less current liabilities | £1,442,429 | £2,125,598 | |
| Net assets | £1,393,027 | £2,106,901 | |
| Equity | £1,393,027 | £2,106,901 | |
| Average employees | 31 | 46 | |
| Wages | — | — |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated (group)
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on a going concern basis, which assumes that Cresset will continue in operational existence for at least twelve months from the date these financial statements are approved. Based on forecasts and stress test scenarios, considering existing funds and the capital raise after the year-end, the Directors determine that Cresset will have sufficient cash for the next twelve months and as such can be considered a going concern.”
Subsidiaries
- Cresset Biomolecular Discovery Inc · 100% held · USA · Development and utilisation of computerised biomolecular modelling
- Cresset Biomolecular Discovery (India) Private Limited · 100% held · India · Development and utilisation of computerised biomolecular modelling
Significant events
- “Cresset acquired Molab.ai GmbH on 18 June 2025, a pioneer in artificial intelligence technologies tailored for molecular research.”
- “Further capital by way of an ordinary share issue of 4,438 shares for consideration of £1,126.68 per share was raised on 14 August 2025 to support the growth plans of the Group.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
8 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SCUTT, Rebecca | Secretary | 2017-05-04 | — | — |
| CHEESERIGHT, Timothy John, Dr | Director | 2013-04-17 | Aug 1966 | British |
| CONROY, Angus Mark | Director | 2022-09-15 | Jun 1988 | British |
| CURTIS JR, Dale | Director | 2024-05-01 | Oct 1976 | American |
| MACKEY, Mark Denis, Dr | Director | 2011-03-16 | Aug 1971 | Australian |
| NEWBLE, David Allan | Director | 2021-10-14 | Jan 1971 | British |
| SCOFFIN, Robert Arthur, Dr | Director | 2010-04-19 | Jan 1966 | British |
| SCUTT, Rebecca Jane | Director | 2020-02-13 | Sep 1974 | British |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HALLS, Raymond David | Secretary | 2001-01-31 | 2005-08-31 |
| ROSE, Valerie Sarah, Dr | Secretary | 2005-09-01 | 2008-08-27 |
| VINTER, Jeremy Gilbert, Dr | Secretary | 2008-08-27 | 2017-05-04 |
| ASHWORTH, Philip Anthony, Dr | Director | 2001-01-31 | 2002-09-10 |
| BARDSLEY, David William, Dr | Director | 2013-04-17 | 2024-05-14 |
| COWEN, Andrew Edward | Director | 2008-10-01 | 2013-04-10 |
| GARDNER, Stephen Philip, Dr | Director | 2011-01-01 | 2013-03-26 |
| HALLS, Raymond David | Director | 2001-01-31 | 2006-07-25 |
| HAYNES, Richard John | Director | 2009-07-14 | 2013-04-08 |
| HILLIER, Paul Ashley | Director | 2001-01-31 | 2006-07-25 |
| LAMONT, Alan Gordon | Director | 2001-11-14 | 2002-07-18 |
| LEIGH, Beatrice Katherine | Director | 2004-05-01 | 2011-09-08 |
| LEIGHTON, John Perrot | Director | 2023-04-11 | 2026-03-23 |
| MCPARTLAND, Peter | Director | 2002-09-01 | 2006-12-20 |
| ROSE, Valerie Sarah, Dr | Director | 2007-05-01 | 2008-08-27 |
| ROSE, Valerie Sarah, Dr | Director | 2004-07-20 | 2006-07-25 |
| VINTER, Jeremy Gilbert, Dr | Director | 2001-01-31 | 2019-12-16 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Sep Vi L.P. | Corporate entity | Shares 25–50%, Voting 25–50% | 2022-09-15 | Active |
| Dr Jeremy Gilbert Vinter | Individual | Shares 25–50% | 2016-04-06 | Ceased 2020-12-08 |
Filing timeline
Last 20 of 202 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-03-23 | TM01 | officers | termination director company with name termination date |
| 2025-12-19 | AA | accounts | accounts with accounts type group |
| 2025-12-18 | SH01 | capital | capital allotment shares |
| 2025-10-21 | SH01 | capital | capital allotment shares |
| 2025-09-30 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-08-21 | SH01 | capital | capital allotment shares |
| 2025-08-21 | MA | incorporation | memorandum articles |
| 2025-08-21 | RESOLUTIONS | resolution | resolution |
| 2025-08-19 | SH01 | capital | capital allotment shares |
| 2025-05-12 | SH01 | capital | capital allotment shares |
| 2025-04-02 | AA | accounts | accounts with accounts type group |
| 2025-03-31 | SH01 | capital | capital allotment shares |
| 2025-01-09 | SH01 | capital | capital allotment shares |
| 2025-01-08 | RP04SH01 | capital | second filing capital allotment shares |
| 2025-01-07 | SH01 | capital | capital allotment shares |
| 2024-12-28 | RESOLUTIONS | resolution | resolution |
| 2024-12-17 | SH01 | capital | capital allotment shares |
| 2024-11-26 | CH01 | officers | change person director company with change date |
| 2024-11-26 | CH01 | officers | change person director company with change date |
| 2024-11-25 | CH01 | officers | change person director company with change date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory